Data di Pubblicazione:
2023
Citazione:
Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies / G. Vitale, S. Carra, Y. Alessi, F. Campolo, C. Pandozzi, I. Zanata, A. Colao, A. Faggiano. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 24:4(2023 Feb 10), pp. 3610.1-3610.22. [10.3390/ijms24043610]
Abstract:
Carcinoid syndrome represents a debilitating paraneoplastic disease, caused by the secretion of several substances, occurring in about 10-40% of patients with well-differentiated neuroendocrine tumors (NETs). The main signs and symptoms associated with carcinoid syndrome are flushing, diarrhea, hypotension, tachycardia, bronchoconstriction, venous telangiectasia, dyspnea and fibrotic complications (mesenteric and retroperitoneal fibrosis, and carcinoid heart disease). Although there are several drugs available for the treatment of carcinoid syndrome, the lack of therapeutic response, poor tolerance or resistance to drugs are often reported. Preclinical models are indispensable tools for investigating the pathogenesis, mechanisms for tumor progression and new therapeutic approaches for cancer. This paper provides a state-of-the-art overview of in vitro and in vivo models in NETs with carcinoid syndrome, highlighting the future developments and therapeutic approaches in this field.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
carcinoid syndrome; neuroendocrine tumors; pharmacological treatment; preclinical models; serotonin; xenograft
Elenco autori:
G. Vitale, S. Carra, Y. Alessi, F. Campolo, C. Pandozzi, I. Zanata, A. Colao, A. Faggiano
Link alla scheda completa: